Allergan has said it is not interested in buying Shire after all, after announcing yesterday that it was considering a bid for the UK-listed firm also targeted by Takeda.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
